raloxifene hydrochloride has been researched along with Hypertrophy in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, LJ; Falcone, JF; Jones, CD | 1 |
| Bekele, A; Bendele, R; Bensch, WR; Black, LJ; Cullinan, GJ; Kauffman, RF; Magee, DE; Rowley, ER; Sato, M; Williams, DC | 1 |
| Carthew, P; Edwards, RE; Nolan, BM | 1 |
3 other study(ies) available for raloxifene hydrochloride and Hypertrophy
| Article | Year |
|---|---|
Antagonism of estrogen action with a new benzothiophene derived antiestrogen.
Topics: Animals; Estradiol; Estrogen Antagonists; Female; Hypertrophy; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Uterus | 1983 |
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Body Weight; Bone Density; Bone Resorption; Calcium; Cholesterol; Dose-Response Relationship, Drug; Epithelial Cells; Epithelium; Estrogen Antagonists; Ethinyl Estradiol; Female; Hypertrophy; Ovariectomy; Phosphorus; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Triglycerides; Uterus | 1994 |
Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse.
Topics: Animals; Anticarcinogenic Agents; Bromodeoxyuridine; Cell Division; Cell Nucleus; Dose-Response Relationship, Drug; Endometrium; Epithelium; Estradiol; Estrogens; Female; Hypertrophy; Mice; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene; Uterus; Vagina | 1999 |